EAM Investors’s Sage Therapeutics SAGE Stock Holding History

EAM Investors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18,221	Closed	-$2.94M	–	345
2018 Q1	$2.94M	Sell	18,221 -1,675	-8%	-$284K	0.49%	95
2017 Q4	$3.28M	Buy	+19,896	New	+$1.93M	0.59%	35
2015 Q4	–	Sell	-38,074	Closed	-$1.61M	–	352
2015 Q3	$1.61M	Sell	38,074 -24,239	-39%	-$1.49M	0.26%	189
2015 Q2	$4.55M	Buy	+62,313	New	+$4.01M	0.53%	42

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EAM Investors's SAGE Position: Q2 2018 in Review

EAM Investors sold out of Sage Therapeutics (SAGE) in Q2 2018, closing a stake of 18,221 shares — an estimated $2.94M sold.

EAM Investors first reported a position in SAGE in Q2 2015 and held it in 4 quarters. The position peaked at $4.55M in Q2 2015. 269 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

EAM Investors reported no remaining Sage Therapeutics position as of Q2 2018 after selling out during the quarter.
EAM Investors sold 18,221 Sage Therapeutics shares in Q2 2018, an estimated $2.94M.
EAM Investors first reported a position in Sage Therapeutics in Q2 2015 and held it in 4 quarters.
EAM Investors's Sage Therapeutics position peaked at $4.55M in Q2 2015.
269 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on EAM Investors's 13F filing for Q2 2018, filed 3 Aug 2018.